
Opinion|Videos|August 13, 2024
The Evaluation of Dupilumab In Chronic Spontaneous Urticaria Treatment
A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- Dupilumab has been evaluated in phase 3 clinical trials in patients with chronic spontaneous urticaria (CSU). What did the data show and what was the FDA’s response to the requested approval?
- There is a Bruton tyrosine kinase (BTK) inhibitor under investigation in CSU. How does the BTK pathway differ from others that are targeted by CSU therapies?
a. BTK inhibitors are currently utilized in other disease states. What are the important clinical considerations with BTK inhibitors that clinicians should know?
b. How would the introduction of an oral therapy for CSU influence your treatment decisions?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
2
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
3
Value-Based Care Interventions and Management of CKD Progression
4
Defining the Role of Rilzabrutinib in ITP Management
5